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Introduction
India has very high rates of ESBL producing gram negative
organisms and co-production of AmpC & OXA makes
majority of antibiotics resistant, leaving carbapenems only
reliable options. In recent times, E.coli and Klebsiella
pneumoniae have also started showing resistance to carba-
penems. Cefepime, a 4th generation cephalosporin, is
stable against AmpC & OXA, but it lacks activity against
ESBL producing organisms. Clavulanate is a highly effec-
tive inhibitor of extended-spectrum beta-lactamases
(ESBLs) in detection tests. A novel combination of Cefe-
pime-tazobactam is expected to increase susceptibility of
Enterobacteriaceae otherwise resistant to cefepime if used
alone.The combination of Cefepime-tazobactam may
effectively cover all three major resistance mechanisms
(AmpC & OXA by cefepime, ESBLs by tazobactam).
Objectives
This study was undertaken to estimate the prevalence of
the ESBL producing gram negative bacilli and to evaluate
the in vitro activity of the newer drug cefepime- tazobac-
tam with piperacillin- tazobactum , cefoperazone sulbac-
tam and carbapenems in a tertiary care cancer centre.
Methods
This study was conducted between January 2012 to June
2012. All the samples were processed and identified
as per routine microbiological methods. Antimicrobial
susceptibility and ESBL confirmation was done following
CLSI guidelines. Sensitivity of Cefepime-tazobactam was
compared with cefepime, cefoperazone-sulbactam,
piperacillin-tazobactam, imipenem, meropenem.
Results
Of the269 isolates included in this study, there were 120
E.coli, 109 Klebsiella pneumoniae and 40 Enterobacter
spp. 141 isolates were ESBL positive and 88 were ESBL




ESBLs are novel beta-lactamases produced by a variety of
gram-negative bacilli. Cefepime-tazobactam can be used
for treatment of ESBL producing Enterobacteriaceae. This
will help to reduce the usage of carbapenems in ESBL
positive Enterobacteriaceae strains and prevent develop-
ment of carbapenem resistance.This combination has
shown good in-vivo response in many patients who were
treated. Further detailed evaluation of this combination is
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